From: The treatment of chronic hepatitis C virus infection in HIV co-infection
Study | Number patients† | Study type | PegIFN Therapy | Patient characteristics | SVR rates | |||||
---|---|---|---|---|---|---|---|---|---|---|
Duration | RBV dosing mg/day | High VL % | GT1% | IDU % | Overall % | GT 1/4% | GT 2/3% | |||
Laguno et al. 2004 [61] | 52 | prospective randomized controlled clinical trial | 24 - 48 | 800 - 1200 | 47* | 49 | 82 | 44 | 38 | 53 |
Nunez et al. 2007 [62] | 389 | prospective clinical trial | 24 - 72 | 1000 - 1200 | 67* | 49 | 90 | 50 | 35 | 72 |
Laguno et al. 2009 [63] | 182 | prospective randomized controlled clinical trial | 48 | 800 - 1200 | 59* | 45 | 76 | 44 | 30 | 66 |
Torriani et al. 2004 [64] | 289 | prospective randomized controlled clinical trial | 48 | 800 | 72* | 61 | 62 | 40 | 29‡ | 62 |
Mira et al. 2009 [65] | 542 | observational cohort study | 24 - 48 | 600 - 1500 | 58* | 54 | 85 | 38 | 25 | 63 |
Rodriguez-Torres et al. 2009 [66] | 410 | prospective randomized controlled clinical trial | 48 | 800 - 1200 | 80* | 100 | n.r. | - | 21 | - |
Voigt et al. 2005 [67] | 122 | prospective clinical trial | 24 - 48 | 800 | 45* | 56 | 61 | 25 | 18 | 44 |
Berenguer et al. 2009 [68] | 557 | observational cohort study | # | # | 61* | 51 | 80 | 32 | 17 | 45 |
Carrat et al. 2004 [69] | 205 | prospective randomized controlled clinical trial | 48 | 800 | 63* | 48 | 80 | 27 | 17 | 44$ |
Chung et al. 2004 [70] | 66 | prospective randomized controlled clinical trial | 48 | 600 - 1000$ | 83* | 77 | not rep. | 27 | 14‡ | 73$ |